Immutep Limited (ASX: IMM) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Immutep Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Immutep Limited (ASX: IMM)
Latest News
Share Gainers
Immutep (ASX:IMM) share price jumps 5% on Chinese patent grant
Healthcare Shares
Why the Immutep (ASX:IMM) share price is charging higher today
Share Market News
Capital keeps flowing into ASX Biotech shares in 2021
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Healthcare Shares
The Immutep (ASX:IMM) share price is up 6% today
Share Fallers
Why the Immutep (ASX:IMM) share price is sinking 16% today
Healthcare Shares
Here's why the Immutep (ASX:IMM) share price is frozen
Healthcare Shares
Why the Immutep (ASX:IMM) share price is marching higher today
Healthcare Shares
Immutep (ASX:IMM) share price backtracks despite patent approval
Healthcare Shares
Immutep (ASX:IMM) share price bounces on new supply deal
Healthcare Shares
Why the Immutep (ASX:IMM) share price rocketed 14% today
Broker Notes
Top brokers name 3 ASX small cap shares to buy
Frequently Asked Questions
-
No, Immutep does not pay dividends at this time.
-
Immutep Ltd listed on the ASX on 23 June 1988.
IMM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Immutep Limited
Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.
